Recent evidence suggests that transgelin/SM22 acts as a tumour suppressor with diminished expression in prostate (Yang et al., 2007), breast (Sayar et al., 2015; Dvorakova et al., 2016), and colon cancers (Assinder et al., 2009; Liu et al., 2020). This evidence concerns the gene TAGLN and neoplasm.